Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026)
Canton Strategic Holdings posted quarterly Change in Accured Expenses of -$1.5 million for Q1 2026, down 22752.21% year-on-year from N/an in Q1 2025, and down 196.73% on a QoQ basis from $1.5 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 22752.21% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$378695.0 (down 147.91% YoY), and the FY2025 full-year result was $1.1 million, up 156.55% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.5 million, down from $1.5 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.5 million in Q4 2025 and bottomed at -$1.5 million in Q1 2026.
- The 5-year median for Change in Accured Expenses is -$6376.0 (2025), against an average of $36530.7.
- The widest annual swing landed in 2023, when Change in Accured Expenses soared 6658.29%; it then sank 22752.21% in 2026.
- A 5-year view of Change in Accured Expenses shows it stood at $10597.0 in 2022, then jumped by 6658.29% to $716176.0 in 2023, then tumbled by 106.25% to -$44774.0 in 2024, then soared by 3464.2% to $1.5 million in 2025, then tumbled by 196.73% to -$1.5 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $1.5 million (Q4 2025), and -$368137.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | -368,137.00 |
| Sep 30, 2025 | -368,137.00 |
| Jun 30, 2025 | -59,787.00 |
| Jun 30, 2025 | -59,787.00 |
| Mar 31, 2025 | -6,376.00 |
| Mar 31, 2025 | -6,376.00 |
| Dec 31, 2024 | -44,774.00 |
| Dec 31, 2024 | -44,774.00 |
| Sep 30, 2024 | 789,628.00 |
| Sep 30, 2024 | 789,628.00 |
| Jun 30, 2024 | 51,935.00 |
| Jun 30, 2024 | 51,935.00 |
| Mar 31, 2024 | -378,942.00 |
| Mar 31, 2024 | -378,942.00 |
| Dec 31, 2023 | 716,176.00 |
| Dec 31, 2023 | 716,176.00 |
| Sep 30, 2023 | 122,424.00 |
| Sep 30, 2023 | 122,424.00 |
| Jun 30, 2023 | -174,351.00 |
| Jun 30, 2023 | -174,351.00 |
| Mar 31, 2023 | 51,752.00 |
| Mar 31, 2023 | 51,752.00 |
| Dec 31, 2022 | 10,597.00 |
| Dec 31, 2022 | 10,597.00 |
| Sep 30, 2022 | -6,073.00 |
| Sep 30, 2022 | -6,073.00 |
| Jun 30, 2022 | -32,941.00 |
| Jun 30, 2022 | -32,941.00 |
| Mar 31, 2022 | -99,338.00 |
| Mar 31, 2022 | -99,338.00 |
| Dec 31, 2021 | 13,362.00 |
| Dec 31, 2021 | 13,362.00 |
| Sep 30, 2021 | 157,551.00 |
| Sep 30, 2021 | 157,551.00 |
| Jun 30, 2021 | -100,876.00 |
| Jun 30, 2021 | -100,876.00 |
| Mar 31, 2021 | 199,409.00 |
| Mar 31, 2021 | 199,409.00 |